Continuum Advisory’s Humana HUM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$92.6K Buy
+233
New +$66.3K 0.01% 654
2025
Q4
Sell
-18,405
Closed -$4.79M 464
2025
Q3
$4.79M Buy
18,405
+2,032
+12% +$534K 0.51% 47
2025
Q2
$4M Buy
16,373
+1,802
+12% +$449K 0.48% 52
2025
Q1
$3.86M Buy
14,571
+369
+3% +$99.8K 0.5% 41
2024
Q4
$3.6M Buy
14,202
+590
+4% +$158K 0.46% 46
2024
Q3
$3.85M Buy
13,612
+13,544
+19,918% +$4.82M 0.49% 42
2024
Q2
$25.4K Sell
68
-60
-47% -$20.3K ﹤0.01% 751
2024
Q1
$42.8K Sell
128
-3,330
-96% -$1.26M 0.01% 630
2023
Q4
$1.58M Buy
3,458
+682
+25% +$336K 0.23% 114
2023
Q3
$1.35M Buy
2,776
+739
+36% +$347K 0.22% 125
2023
Q2
$911K Buy
+2,037
New +$1.03M 0.14% 176
2023
Q1
Sell
-951
Closed -$487K 433
2022
Q4
$487K Buy
951
+119
+14% +$62.5K 0.09% 260
2022
Q3
$404K Buy
832
+53
+7% +$25.8K 0.07% 276
2022
Q2
$365K Buy
779
+184
+31% +$81.9K 0.07% 299
2022
Q1
$265K Buy
+595
New +$249K 0.05% 333

Other funds holding HUM

Continuum Advisory's HUM Position: Q2 2026 in Review

Continuum Advisory opened a new position in Humana (HUM) in Q2 2026: 233 shares worth $92.6K. The stake represents 0.01% of the portfolio and ranks #654 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in HUM as recently as Q3 2025.

Continuum Advisory first reported a position in HUM in Q1 2022 and has held it in 15 quarters since. The position peaked at $4.79M in Q3 2025. 926 funds tracked by Wall St. Rank hold HUM as of Q2 2026.

  • Continuum Advisory held 233 shares of Humana worth $92.6K as of Q2 2026.
  • Humana was a new Continuum Advisory position in Q2 2026.
  • Humana made up 0.01% of Continuum Advisory's portfolio in Q2 2026, its #654 holding.
  • Continuum Advisory first reported a position in Humana in Q1 2022 and has held it in 15 quarters since.
  • Continuum Advisory's Humana position peaked at $4.79M in Q3 2025.
  • 926 funds tracked by Wall St. Rank held Humana as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.